Literature DB >> 7463333

Analysis of 4'-demethylepipodophyllotoxin-9-(4,6-O-ethylidene-beta-D-glucopyranoside) by high-pressure liquid chromatography.

L M Allen.   

Abstract

A rapid and specific high-pressure liquid chromatographic assay is described for the quantitative analysis of 4'-demethylepipodophyllotoxin-9-(4,6-O-ethylidene-beta-D-glucopyranoside) (I) in plasma. After chloroform extraction, I was analyzed by reversed-phase chromatography and UV detection (252nm). The maximum sensitivity was 0.1 microgram/ml. Quantitation was by relative response factor calibration using an integrating microcomputer. Over the concentration range of 0.5-90 microgram/ml, the average recovery of I from plasma was 95.4 +/- 3.8% (SD).

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7463333     DOI: 10.1002/jps.2600691225

Source DB:  PubMed          Journal:  J Pharm Sci        ISSN: 0022-3549            Impact factor:   3.534


  6 in total

Review 1.  The clinical pharmacology of VM26 and VP16-213. A brief overview.

Authors:  P J Creaven
Journal:  Cancer Chemother Pharmacol       Date:  1982       Impact factor: 3.333

Review 2.  Etoposide and teniposide. Bioanalysis, metabolism and clinical pharmacokinetics.

Authors:  J J Holthuis
Journal:  Pharm Weekbl Sci       Date:  1988-06-17

3.  Combination chemotherapy of the epipodophyllotoxin derivatives, teniposide and etoposide. A pharmacodynamic rationale?

Authors:  L M Allen; F Tejada; A D Okonmah; S Nordqvist
Journal:  Cancer Chemother Pharmacol       Date:  1982       Impact factor: 3.333

4.  Pharmacokinetics of VP16-213 given by different administration methods.

Authors:  M D'Incalci; P Farina; C Sessa; C Mangioni; V Conter; G Masera; M Rocchetti; M B Pisoni; E Piazza; M Beer; F Cavalli
Journal:  Cancer Chemother Pharmacol       Date:  1982       Impact factor: 3.333

Review 5.  The clinical pharmacology of etoposide and teniposide.

Authors:  P I Clark; M L Slevin
Journal:  Clin Pharmacokinet       Date:  1987-04       Impact factor: 6.447

6.  Phase I study and clinical pharmacological evaluation of daily oral etoposide combined with carboplatin in patients with lung cancer.

Authors:  T Ohune; Y Fujiwara; H Sumiyoshi; N Yamaoka; M Yamakido
Journal:  Jpn J Cancer Res       Date:  1995-05
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.